Karl Claxton
Professor of health economics at the University of York, specialising in cost-effectiveness analysis and health technology assessment with extensive experience on NICE appraisal processes.
Best podcasts with Karl Claxton
Ranked by the Snipd community
May 1, 2026 • 43min
The US UK trade deal will cost the NHS billions, and only serve to increase pharma profits
Sally Gainsbury, senior policy analyst at Nuffield Trust, and Karl Claxton, health economics professor at University of York, unpack the US–UK medicines trade deal. They discuss how the deal forces big NHS drug spending rises. They explain changes to NICE thresholds, rebates, and how costs may be shifted from services to pharmaceuticals.
